Shakti H Ramkissoon
Overview
Explore the profile of Shakti H Ramkissoon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
3910
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dorsey J, Mott R, Lack C, Britt N, Ramkissoon S, Morris B, et al.
Oncol Lett
. 2022 Aug;
24(3):326.
PMID: 35949590
Gorlin syndrome or nevoid basal cell carcinoma syndrome is a rare genetic disease characterized by predisposition to congenital defects, basal cell carcinomas and medulloblastoma. The syndrome results from a heritable...
12.
Ramkissoon S, Fernandes H, Lopez-Terrada D, Hameed M, Trembath D, Bridge J, et al.
Arch Pathol Lab Med
. 2022 Jul;
147(5):518-524.
PMID: 35878398
Context.—: Integration of molecular data into glioma classification supports diagnostic, prognostic, and therapeutic decision-making; however, testing practices for these informative biomarkers in clinical laboratories remain unclear. Objective.—: To examine the...
13.
Ashok Kumar P, Graziano S, Danziger N, Pavlick D, Severson E, Ramkissoon S, et al.
Cancer Med
. 2022 Jun;
12(2):1157-1166.
PMID: 35747993
Introduction: New treatment strategies for advanced non-small-cell lung carcinoma (NSCLC) include synthetic lethality targets focused on protein arginine methyl transferases such as PRMT5 that exploit the impact of genomic loss...
14.
Papillon-Cavanagh S, Hopkins J, Ramkissoon S, Albacker L, Walsh A
Commun Med (Lond)
. 2022 May;
1:56.
PMID: 35602225
Background: Tumor mutational burden (TMB) has been proposed as a predictive biomarker of response to immunotherapy. Efforts to standardize TMB scores for use in the clinic and to identify the...
15.
Abousaud M, Faroqui N, Lesser G, Strowd R, Ramkissoon S, Kwatra M, et al.
J Cancer Sci Clin Ther
. 2022 May;
5(2):210-220.
PMID: 35601813
Background: alterations are commonly observed in malignant gliomas (MG). Osimertinib, an irreversible EGFR-tyrosine kinase inhibitor, effectively penetrates the blood brain barrier and achieves therapeutic concentrations in brain tissue. Materials And...
16.
Huang R, Harries L, Decker B, Hiemenz M, Murugesan K, Creeden J, et al.
Oncologist
. 2022 May;
27(10):839-848.
PMID: 35598205
Background: In patients with non-small cell lung cancer (NSCLC), 10%-40% will eventually develop brain metastases. We present the clinicopathologic, genomic, and biomarker landscape of a large cohort of NSCLC brain...
17.
Huang R, Tse J, Harries L, Graf R, Lin D, Murugesan K, et al.
Oncologist
. 2022 May;
27(8):655-662.
PMID: 35552752
Background: In the current study, we examined the real-world prevalence of highly pigmented advanced melanomas (HPMel) and the clinicopathologic, genomic, and ICPI biomarker signatures of this class of tumors. Materials...
18.
Azam S, Ballester L, Ramkissoon S, Hsu S, Zhu J, Qualmann K
JCO Precis Oncol
. 2022 Feb;
3:1-6.
PMID: 35100712
No abstract available.
19.
Williams E, Montesion M, Lincoln V, Tse J, Hiemenz M, Mata D, et al.
Am J Surg Pathol
. 2022 Jan;
46(6):729-741.
PMID: 35034043
Inactivating mutations in tumor suppressor genes TP53 and RB1 are considered central drivers in leiomyosarcomas (LMSs). In high-risk human papillomavirus (HPV)-related tumors, a similar functional outcome is achieved through oncoproteins...
20.
Lin D, Fine A, Danziger N, Huang R, Mata D, Decker B, et al.
Gynecol Oncol
. 2022 Jan;
164(3):558-565.
PMID: 34998597
Objectives: Endometrial serous carcinoma (EMSC) is an aggressive variant of uterine cancer with limited therapeutic options. We sought to define distinct clinicopathologic and genomic EMSC subgroups. Methods: We retrospectively analyzed...